Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research
Ischemic stroke and traumatic brain injury (TBI) are among the leading causes of death and disability worldwide with impairments ranging from mild to severe. Many therapies are aimed at improving functional and cognitive recovery by targeting neural repair but have encountered issues involving effic...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Neural Plasticity |
| Online Access: | http://dx.doi.org/10.1155/2022/3889300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559493515313152 |
|---|---|
| author | Serena-Kaye Sims Brynna Wilken-Resman Crystal J. Smith Ashley Mitchell Lilly McGonegal Catrina Sims-Robinson |
| author_facet | Serena-Kaye Sims Brynna Wilken-Resman Crystal J. Smith Ashley Mitchell Lilly McGonegal Catrina Sims-Robinson |
| author_sort | Serena-Kaye Sims |
| collection | DOAJ |
| description | Ischemic stroke and traumatic brain injury (TBI) are among the leading causes of death and disability worldwide with impairments ranging from mild to severe. Many therapies are aimed at improving functional and cognitive recovery by targeting neural repair but have encountered issues involving efficacy and drug delivery. As a result, therapeutic options for patients are sparse. Neurotrophic factors are one of the key mediators of neural plasticity and functional recovery. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) serve as potential therapeutic options to increase neural repair and recovery as they promote neuroprotection and regeneration. BDNF and NGF have demonstrated the ability to improve functional recovery in preclinical and to a lesser extent clinical studies. Direct and indirect methods to increase levels of neurotrophic factors in animal models have been successful in improving postinjury outcome measures. However, the translation of these studies into clinical trials has been limited. Preclinical experiments have largely failed to result in significant impacts in clinical research. This review will focus on the administration of these neurotrophic factors in preclinical and clinical stroke and TBI and the challenges in translating these therapies from the bench to the clinic. |
| format | Article |
| id | doaj-art-7edce9cb67cb4c58aa42c18ba608fede |
| institution | Kabale University |
| issn | 1687-5443 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neural Plasticity |
| spelling | doaj-art-7edce9cb67cb4c58aa42c18ba608fede2025-02-03T01:29:53ZengWileyNeural Plasticity1687-54432022-01-01202210.1155/2022/3889300Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical ResearchSerena-Kaye Sims0Brynna Wilken-Resman1Crystal J. Smith2Ashley Mitchell3Lilly McGonegal4Catrina Sims-Robinson5Medical University of South CarolinaMedical University of South CarolinaMedical University of South CarolinaMedical University of South CarolinaCollege of CharlestonMedical University of South CarolinaIschemic stroke and traumatic brain injury (TBI) are among the leading causes of death and disability worldwide with impairments ranging from mild to severe. Many therapies are aimed at improving functional and cognitive recovery by targeting neural repair but have encountered issues involving efficacy and drug delivery. As a result, therapeutic options for patients are sparse. Neurotrophic factors are one of the key mediators of neural plasticity and functional recovery. Neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) serve as potential therapeutic options to increase neural repair and recovery as they promote neuroprotection and regeneration. BDNF and NGF have demonstrated the ability to improve functional recovery in preclinical and to a lesser extent clinical studies. Direct and indirect methods to increase levels of neurotrophic factors in animal models have been successful in improving postinjury outcome measures. However, the translation of these studies into clinical trials has been limited. Preclinical experiments have largely failed to result in significant impacts in clinical research. This review will focus on the administration of these neurotrophic factors in preclinical and clinical stroke and TBI and the challenges in translating these therapies from the bench to the clinic.http://dx.doi.org/10.1155/2022/3889300 |
| spellingShingle | Serena-Kaye Sims Brynna Wilken-Resman Crystal J. Smith Ashley Mitchell Lilly McGonegal Catrina Sims-Robinson Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research Neural Plasticity |
| title | Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research |
| title_full | Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research |
| title_fullStr | Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research |
| title_full_unstemmed | Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research |
| title_short | Brain-Derived Neurotrophic Factor and Nerve Growth Factor Therapeutics for Brain Injury: The Current Translational Challenges in Preclinical and Clinical Research |
| title_sort | brain derived neurotrophic factor and nerve growth factor therapeutics for brain injury the current translational challenges in preclinical and clinical research |
| url | http://dx.doi.org/10.1155/2022/3889300 |
| work_keys_str_mv | AT serenakayesims brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch AT brynnawilkenresman brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch AT crystaljsmith brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch AT ashleymitchell brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch AT lillymcgonegal brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch AT catrinasimsrobinson brainderivedneurotrophicfactorandnervegrowthfactortherapeuticsforbraininjurythecurrenttranslationalchallengesinpreclinicalandclinicalresearch |